255 results found.

Non Small Cell Lung Cancer (NSCLC) Clinical Trial using MK-3475; Docetaxel

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer.
MK-3475; Docetaxel

Non- Small Cell Lung Cancer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pilot Study of Inpatient Hospice With Procurement of Tissue on Expiration in Thoracic Malignancies.

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
afatinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using Afatinib

Boehringer Ingelheim - Recruiting 18 years or older.
- An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s).
Afatinib

Non-Small Cell Lung Cancer Clinical Trial using Denosumab; Zometa

Amgen - Recruiting 18 years or older.
- A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer.
Denosumab; Zometa

Non-small Cell Lung Cancer Clinical Trial using MK-3475

Merck Sharp & Dohme Corp. - Recruiting 20 years or older.
- An Open-label, Non-randomized, Multi-center Phase Ib Study of MK-3475 in Subjects With PD-L1 Positive Advanced Non-Small Cell Lung Cancer.
MK-3475

Carcinoma, Non-Small-Cell Lung Clinical Trial using Dose escalation followed by treatment with MTD

Boehringer Ingelheim - Recruiting 18 years or older.
- A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations.
Dose escalation followed by treatment with MTD

Non-Small Cell Lung Cancer, Anemia, Cancer, or Lung Cancer Clinical Trial using darbepoetin alfa 500 mcg Q3W; placebo

Amgen - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy.
darbepoetin alfa 500 mcg Q3W; placebo

Cancer, Solid Tumor Clinical Trial using MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma.
MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Recurrent Non-small Cell Lung Cancer, or Stage IV Non-small Cell Clinical Trial using cabozantinib-s-malate; erlotinib hydrochloride; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients With Advanced EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy.
cabozantinib-s-malate; erlotinib hydrochloride; laboratory biomarker analysis

Recurrent Small Cell Lung Cancer Clinical Trial using veliparib; temozolomide; placebo; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Multi-center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer.
veliparib; temozolomide; placebo; laboratory biomarker analysis

Non-Small Cell Lung Cancer Clinical Trial using onartuzumab [MetMAb]; erlotinib [Tarceva]; Placebo

Genentech - Recruiting 18 years or older.
- A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Standard Chemotherapy for Advanced/Metastatic Disease.
onartuzumab [MetMAb]; erlotinib [Tarceva]; Placebo

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A

Genentech - Recruiting 18 years or older.
- A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer.
MPDL3280A

Non-Small Cell Lung Cancer, Ovarian Cancer Clinical Trial using DNIB0600A

Genentech - Recruiting 18 years or older.
- A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
DNIB0600A

Non-Small Cell Lung Cancer Clinical Trial using GDC-0941; carboplatin; paclitaxel; bevacizumab; Placebo

Genentech - Recruiting 18 years or older.
- A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer.
GDC-0941; carboplatin; paclitaxel; bevacizumab; Placebo

Lung Neoplasm, or Cell Hypoxia Clinical Trial using 18F-FAZA; 18F-Fluorodeoxyglucose (18F-FDG)

AHS Cancer Control Alberta - Recruiting 18 years or older.
- A Study to See if a New Type of Imaging Can Help Our Understanding of the Course of Non-small Cell Lung Cancer in Patients Undergoing Treatment With Radiotherapy or Chemoradiotherapy.
18F-FAZA; 18F-Fluorodeoxyglucose (18F-FDG)

Non-small Cell Lung Carcinoma Clinical Trial using chemotherapy

Yonsei University - Recruiting 18 years or older.
- .
chemotherapy

Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Clinical Trial

Cancer Centre of Monoclonal Therapy, LLC - Recruiting 18 years or older.
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors.

Stage III Non-small Cell Lung Cancer Clinical Trial using 1 MRI scan

UMC Utrecht - Recruiting 18 years or older.
- MRI for Radiotherapy Treatment Planning of Stage III NSCLC: an MRI Optimization Study in Healthy Volunteers and Patients.
1 MRI scan

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A; docetaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER FAILURE WITH PLATINUM-CONTAINING CHEMOTHERAPY.
MPDL3280A; docetaxel

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF MPDL3280A IN PATIENTS WITH PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER.
MPDL3280A

Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Ca Clinical Trial using Docetaxel; HyperAcuter-Lung Immunotherapy; Gemcitabine; Pemetrexed

NewLink Genetics Corporation - Recruiting 18 years or older.
- An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Hyper-Acute(R)-Lung (Tergenpumatucel-L) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer.
Docetaxel; HyperAcuter-Lung Immunotherapy; Gemcitabine; Pemetrexed

Non Small Cell Lung Cancer, ROS1 Proto Oncogene, or Crizotinib Clinical Trial using Crizotinib

OxOnc Development LP - Recruiting 18 years or older.
- Phase II, Open Label, Single Arm Study of the Efficacy and Safety of Crizotinib in East Asian Patients With Advanced ALK-Negative NSCLC Harboring a Translocation or Inversion Involving the c-ROS Oncogene (ROS1) Locus.
Crizotinib

Non-Small Cell Lung Cancer Clinical Trial using Cabozantinib

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer.
Cabozantinib

Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lu Clinical Trial using positron emission tomography; computed tomography; intensity-modulated radiation therapy; carboplatin; paclitaxel

Albert Einstein College of Medicine of Yeshiva University - Recruiting 18 years or older.
- PET-Adjusted IMRT for NSCLC Trial (PAINT).
positron emission tomography; computed tomography; intensity-modulated radiation therapy; carboplatin; paclitaxel

Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Clinical Trial using bavituximab; Docetaxel; Placebo (for bavituximab)

Peregrine Pharmaceuticals - Recruiting 18 years or older.
- SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone as Second-Line Therapy in Patients With Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer.
bavituximab; Docetaxel; Placebo (for bavituximab)

Non-small Cell Lung Cancer Clinical Trial using INC280

Novartis - Recruiting 18 years or older.
- A Phase IB/II, Open Label, Multicenter Study of INC280 Administered Orally in Combination With Gefitinib in Adult Patients With EGFR Mutated, c-MET-amplified Non-small Cell Lung Cancer Who Have Progressed After EGFR Inhibitor Treatment.
INC280

Non-small Cell Lung Cancer Clinical Trial using Nivolumab; Gemcitabine; Cisplatin; Pemetrexed; Paclitaxel; Carboplatin; Bevacizumab; Erlotinib; Ipilimumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Multi-arm Phase I Safety Study of Nivolumab in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC).
Nivolumab; Gemcitabine; Cisplatin; Pemetrexed; Paclitaxel; Carboplatin; Bevacizumab; Erlotinib; Ipilimumab

Non-Small Cell Lung Cancer Clinical Trial using RO5424802

Hoffmann-La Roche - Recruiting 18 years or older.
- A Phase I/II Study of the ALK Inhibitor CH5424802/ RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib.
RO5424802

Non-Small Cell Lung Cancer Clinical Trial using erlotinib; placebo; onartuzumab

Hoffmann-La Roche - Recruiting 18 years or older.
- A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB IN COMBINATION WITH ERLOTINIB AS FIRST-LINE TREATMENT FOR PATIENTS WITH MET-POSITIVE UNRESECTABLE STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING AN ACTIVATING EGFR MUTATION.
erlotinib; placebo; onartuzumab

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]; Placebo

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of First-line Maintenance Tarceva vs Tarceva at the Time of Disease Progression in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following 4 Cycles of Platinum-based Chemotherapy.
erlotinib [Tarceva]; Placebo

ALK Positive Non Small Cell Lung Cancer Clinical Trial using PF-06463922

Pfizer - Recruiting 18 years or older.
- Phase 1/2 Study Of PF-06463922 (An ALK/ROS1 Tyrosine Kinase Inhibitor) In Patients With Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations.
PF-06463922

Solid Tumour,, Breast Cancer,, Metastatic Melanoma,, or Non-small Clinical Trial using F16IL2 in combination with paclitaxel

Philogen S.p.A. - Recruiting 18 years or older.
- Phase Ib/II Study of the Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Advanced Solid Tumours.
F16IL2 in combination with paclitaxel

Non-Small Cell Lung Cancer Clinical Trial using Erlotinib [Tarceva]; gemcitabine; cisplatin

Hoffmann-La Roche - Recruiting 18 years or older.
- ENSURE Extension Study to Assess the PFS of First-Line Erlotinib (Tarceva) and Erlotinib After Disease Progression in Chinese Population Enrolled in the ENSURE Trial.
Erlotinib [Tarceva]; gemcitabine; cisplatin

Non Small Cell Lung Cancer Clinical Trial using DCE-MRI scan; Stereotactic Body Radiation Therapy; 4D-CT scan

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Feasibility Study of the Utility of Pulmonary Dynamic Contrast Enhanced MRI for Assessment of Tumor Response and Lung Injury and for Treatment Planning for Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer.
DCE-MRI scan; Stereotactic Body Radiation Therapy; 4D-CT scan

Non-Small Cell Lung Cancer Clinical Trial using LDK378

Novartis - Recruiting 18 years or older.
- A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib na‹ve Adult Patients With ALK-activated Non-small Cell Lung Cancer.
LDK378

Lung Cancer Clinical Trial using panitumumab; carboplatin; paclitaxel

Radiation Therapy Oncology Group - Recruiting 18 years or older.
- Randomized Phase II Study of Pre-operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed by Consolidation Chemotherapy +/- Cetuximab in Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10).
panitumumab; carboplatin; paclitaxel

Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Clinical Trial using CB-839

Calithera Biosciences, Inc - Recruiting 18 years or older.
- A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors.
CB-839

NSCLC Clinical Trial using afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)

Samsung Medical Center - Recruiting 20 years or older.
- A Phase Ib Study of Afatinib Plus Nimotuzumab in Non-small Cell Lung Cancer Patients Who Progressed With Reversible EGFR TKI.
afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)

Non-small Cell Lung Cancer Metastatic Clinical Trial using Ramucirumab; Placebo; Docetaxel

Eli Lilly and Company - Recruiting 20 years or older.
- A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy.
Ramucirumab; Placebo; Docetaxel

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

AstraZeneca - Recruiting 18 years or older.
- A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1).
Selumetinib; Docetaxel; Placebo; Pegylated G-CSF

Neoplasms,, Metastatic Cancer,, Non-Small Cell Lung Cancer, or Ad Clinical Trial using AZD6244; Docetaxel

AstraZeneca - Recruiting 20 years or older.
- A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given as a Monotherapy in Japanese Patients With Advanced Solid Malignancies, and When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV).
AZD6244; Docetaxel

Anxiety Disorder, Recurrent Non-small Cell Lung Cancer, or Stage Clinical Trial using counseling intervention; questionnaire administration; quality-of-life assessment

Stanford University - Recruiting N/A or older.
- Intervention Development for Anxiety in Metastatic NSCLC Patients and Their Caregivers.
counseling intervention; questionnaire administration; quality-of-life assessment

Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lu Clinical Trial using HPPH; therapeutic conventional surgery; photodynamic therapy

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) With Temoporfin in Patients With Resectable Primary Non-Small Cell Lung Cancer (NSCLC) With Ipsilateral Thoracic Nodal (N1 or N2) or T3/T4 Disease.
HPPH; therapeutic conventional surgery; photodynamic therapy

Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lu Clinical Trial using photon beam radiation therapy; proton beam radiation therapy; paclitaxel; carboplatin; etoposide; cisplatin; quality-of-life assessment; questionnaire administration

Radiation Therapy Oncology Group - Recruiting 18 years or older.
- Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC.
photon beam radiation therapy; proton beam radiation therapy; paclitaxel; carboplatin; etoposide; cisplatin; quality-of-life assessment; questionnaire administration

Solid Tumor, or Non-small Cell Lung Cancer Clinical Trial using MK-3475; Cisplatin; Pemetrexed; Carboplatin; Paclitaxel

Merck Sharp & Dohme Corp. - Recruiting 20 years or older.
- A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Cisplatin/Pemetrexed or Carboplatin/Paclitaxel in Subjects With Advanced Non-Small Cell Lung Cancer.
MK-3475; Cisplatin; Pemetrexed; Carboplatin; Paclitaxel

Small Cell Lung Carcinoma, or Malignant Epithelial Neoplasms Clinical Trial using (Belinostat) (PDX101); Cisplatin; Etoposide

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With a Focus on Small Cell Lung Cancer and Other Cancers of Neuroendocrine Origin.
(Belinostat) (PDX101); Cisplatin; Etoposide

Non-small Cell Lung Cancer Metastatic Clinical Trial using carboplatin; paclitaxel; ABP 215; bevacizumab

Amgen - Recruiting 18 years to 80 years.
- A Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer.
carboplatin; paclitaxel; ABP 215; bevacizumab

Lung Cancer Clinical Trial using pemetrexed plus cisplatin; vinorelbine and docetaxel

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- Phase II Trial of Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN).
pemetrexed plus cisplatin; vinorelbine and docetaxel

Lung Neoplasms Clinical Trial using Radiation Concurrent Chemotherapy

Proton Collaborative Group - Recruiting 18 years or older.
- A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer.
Radiation Concurrent Chemotherapy

Non Small Cell Lung Cancer Clinical Trial using AZD6244

Christie Hospital NHS Foundation Trust - Recruiting 18 years or older.
- Phase I Trial of the MEK Inhibitor AZD6244 in Combination With Thoracic Radiotherapy in Non-small Cell Lung Cancer.
AZD6244

Small Cell Lung Carcinoma Clinical Trial using BAY1000394; Etoposide; Cisplatin; Carboplatin

Bayer - Recruiting 18 years or older.
- Phase Ib / II Study of BAY 1000394 in Combination With Cisplatin / Etoposide or Carboplatin / Etoposide as First-line Therapy in Subjects With Extensive Disease Small Cell Lung Cancer.
BAY1000394; Etoposide; Cisplatin; Carboplatin

Anaplastic Lymphoma Kinase (ALK), or Non-small Cell Lung Cancer Clinical Trial using LDK378; AUY922

Novartis - Recruiting 18 years or older.
- A Phase Ib, Open-label, Dose Escalation Study of LDK378 and AUY922 in Patients With ALK-rearranged Non-small Cell Lung Cancer.
LDK378; AUY922

Non Small Cell Lung Cancer, or 4D CT Clinical Trial using Stereotactic Radiosurgery

University of Pittsburgh - Recruiting 18 years or older.
- An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPMT) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System.
Stereotactic Radiosurgery

Non Small Cell Lung Cancer Clinical Trial using Pemetrexed and Reolysin (and safety run-in); Pemetrexed; Docetaxel and Reolysin; Docetaxel

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy..
Pemetrexed and Reolysin (and safety run-in); Pemetrexed; Docetaxel and Reolysin; Docetaxel

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 65 years or older.
- Therapeutic Strategies Including Avastin as 1st Line Therapy in Elderly Patients Suffering From Advanced (IIIB/IV Stage) Non-squamous Non-small Cell Lung Cancer, in Routine Clinical Practice..

Non-Small Cell Lung Cancer Clinical Trial using MPDL3280A; docetaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE II STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER PLATINUM FAILURE.
MPDL3280A; docetaxel

Non-Small Cell Lung Cancer Clinical Trial using RO5452802; erlotinib [Tarceva]

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON - SMALL CELL LUNG CANCER PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT.
RO5452802; erlotinib [Tarceva]

Non-Small Cell Lunch Cancer Clinical Trial using BKM120; placebo; Carboplatin; Paclitaxel

Novartis - Recruiting 18 years or older.
- A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology.
BKM120; placebo; Carboplatin; Paclitaxel

Solid Tumors, Lymphoma, or Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib; Gefitinib

Eli Lilly and Company - Recruiting 20 years or older.
- A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies.
LY2875358; Erlotinib; Gefitinib

Advanced Castrate-resistant Prostate Cancer (CRPC);, Squamous Non Clinical Trial using AZD8186

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient Advanced Solid Malignancies, With Expansion to Assess the Pharmacodynamic Activity of AZD8186 Within Prospectively-validated PTEN Deficient Tumours.
AZD8186

Advanced Non Small Cell Lung Cancer, or Advanced (Inoperable) Non Clinical Trial using AZD9291

AstraZeneca - Recruiting 18 years or older.
- Safety, Tolerability, Pharmacokinetics & Antitumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Have Progressed on Prior Therapy With an Epidermal Growth Factor ReceptorTyrosine Kinase Inhibator Agent.
AZD9291

Lung Cancer, Small Cell Clinical Trial using GSK2879552

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase I Open-label, Dose Escalation Study to Investigate The Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma.
GSK2879552

Cancer Clinical Trial using Dabrafenib; Trametinib

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Dabrafenib; Trametinib

Lung Cancer, Non-Small Cell Clinical Trial using Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A; Placebo

GlaxoSmithKline - Recruiting 18 years or older.
- GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer.
Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A; Placebo

Non-small Cell Lung Cancer Clinical Trial using Stereotactic Body Radiotherapy (SBRT); Conventional Radiotherapy (CRT)

Ontario Clinical Oncology Group (OCOG) - Recruiting 18 years or older.
- A Randomized Trial of Medically-Inoperable Stage 1 Non-small Cell Lung Cancer Patients Comparing Stereotactic Body Radiotherapy Versus Conventional Radiotherapy.
Stereotactic Body Radiotherapy (SBRT); Conventional Radiotherapy (CRT)

Non-small Cell Lung Cancer Clinical Trial using Biopsy of the major carinal area; Biopsy of abnormal & suspicious areas of the bronchial tree; Evaluation of the tumor for DNA mutations; Bronchoalveolar Lavage (BAL) for cytokine analysis; Correlation of flow cytometric & RT PCR for TNM stage; Analysis of lymph nodes

University of Pittsburgh - Recruiting 18 years to 85 years.
- Detection of Genetic Markers of Lung Cancer Initiation and Progression.
Biopsy of the major carinal area; Biopsy of abnormal & suspicious areas of the bronchial tree; Evaluation of the tumor for DNA mutations; Bronchoalveolar Lavage (BAL) for cytokine analysis; Correlation of flow cytometric & RT PCR for TNM stage; Analysis of lymph nodes

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

AstraZeneca - Recruiting 18 years or older.
- A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC).
selumetinib; gemcitabine; cisplatin; carboplatin; pemetrexed

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage I Clinical Trial using Selumetinib 75 mg; Docetaxel 75 mg/m2; Docetaxel 60 mg/m2; Placebo

AstraZeneca - Recruiting 18 years or older.
- A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV).
Selumetinib 75 mg; Docetaxel 75 mg/m2; Docetaxel 60 mg/m2; Placebo

Non Squamous Non Small Cell Lung Cancer Clinical Trial using OGX-427; Placebo

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- Double-Blind Randomized Phase II Trial of Carboplatin and Pemetrexed With or Without OGX-427 in Patients With Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (The Spruce Clinical Trial).
OGX-427; Placebo

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Observational, Post-authorization, Prospective Study for Evaluating Patterns of Disease Progression in Patients With Advanced Non-small-cell Lung Carcinoma (NSCLC) Harbouring EGFR Activating Mutations Treated With Erlotinib in First Line..

Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Lar Clinical Trial using PI3K inhibitor BKM120; pemetrexed disodium; carboplatin; laboratory biomarker analysis; pharmacological study; quality-of-life assessment

City of Hope Medical Center - Recruiting 18 years or older.
- Phase I Trial of BKM120 in Combination With Carboplatin and Pemetrexed in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC).
PI3K inhibitor BKM120; pemetrexed disodium; carboplatin; laboratory biomarker analysis; pharmacological study; quality-of-life assessment

Non-Small Cell Lung Cancer Clinical Trial using Tarceva (erlotinib)

Albert Einstein College of Medicine of Yeshiva University - Recruiting 18 years or older.
- EValuation of Erlotinib as a Neoadjuvant Therapy in Stage III Non-small Cell Lung Cancer Patients With EGFR Mutations (EVENT Trial)..
Tarceva (erlotinib)

Carcinoma, Non-Small Cell Lung Clinical Trial using Radiation Therapy and EGFR-TKI target therapy

Tianjin Medical University Cancer Institute and Hospital - Recruiting 18 years to 70 years.
- A Phase II Study on the Safety and Efficacy of Radiation Therapy and Concurrent Erlotinib in Locally Advanced Non-small-cell Lung Cancer.
Radiation Therapy and EGFR-TKI target therapy

Squamous Non-small Cell Lung Cancer Clinical Trial using Buparlisib; Buparlisib matching placebo; Docetaxel

Novartis - Recruiting 18 years or older.
- A Phase Ib/II Study of Docetaxel With or Without Buparlisib as Second Line Therapy for Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer.
Buparlisib; Buparlisib matching placebo; Docetaxel

Recurrent Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lu Clinical Trial using trametinib; carboplatin; paclitaxel; intensity-modulated radiation therapy; 3-dimensional conformal radiation therapy; image-guided radiation therapy; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-Small Cell Lung Cancer.
trametinib; carboplatin; paclitaxel; intensity-modulated radiation therapy; 3-dimensional conformal radiation therapy; image-guided radiation therapy; pharmacological study; laboratory biomarker analysis

Non-small Cell Lung Cancer Clinical Trial using clinical observation; adjuvant therapy; 3-dimensional conformal radiation therapy

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- Phase III Study Comparing Post-Operative Conformal Radiotherapy to No Post-Operative Radiotherapy in Patients With Completely Resected Non-Small Cell Lung Cancer and Mediastinal N2 Involvement [Lung ART].
clinical observation; adjuvant therapy; 3-dimensional conformal radiation therapy

Non-Small Cell Lung Cancer Clinical Trial using Bortezomib; Acyclovir

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase 2 Trial of Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D.
Bortezomib; Acyclovir

Carcinoma, Non-Small-Cell Lung Clinical Trial using PF-02341066

Pfizer - Recruiting 18 years or older.
- Phase 2, Open-Label Single Arm Study Of The Efficacy And Safety Of PF-02341066 In Patients With Non-Small Cell Lung Cancer Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene.
PF-02341066

NSCLC (Non-small Cell Lung Cancer) Clinical Trial using Crizotinib; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin

Pfizer - Recruiting 18 years to 70 years.
- Phase 3, Randomized, Open-Label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated East Asian Patients With Non-Squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (ALK) Gene Locus.
Crizotinib; Pemetrexed/Cisplatin; Pemetrexed/Carboplatin

Lung Cancer Clinical Trial using bevacizumab; emepepimut-S; carboplatin; cyclophosphamide; paclitaxel; radiation therapy

Eastern Cooperative Oncology Group - Recruiting 18 years or older.
- A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation.
bevacizumab; emepepimut-S; carboplatin; cyclophosphamide; paclitaxel; radiation therapy

Non-Small Cell Lung Carcinoma Clinical Trial using CV9202

CureVac GmbH - Recruiting 18 years or older.
- An Exploratory, Open-label Phase Ib Study of RNActiver-Derived Cancer Vaccine and Local Radiation as Consolidation and Maintenance Treatment in Patients With Stage IV NSCLC and a Response or Stable Disease After First-line Chemotherapy or Therapy With an EGFR Tyrosine Kinase Inhibitor.
CV9202

Carcinoma Clinical Trial

Onkovis GmbH - Recruiting N/A or older.
- Open, Multicenter Observational Study of Paclitaxel Utilized in Mono- or Combination Therapy for the Treatment of Breast Cancer, Non-small Cell Lung Cancer and Ovarial Cancer..

Recurrent Small Cell Lung Cancer Clinical Trial using etirinotecan pegol (NKTR 102); pharmacogenomic studies; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer.
etirinotecan pegol (NKTR 102); pharmacogenomic studies; laboratory biomarker analysis

Non-Small Cell Lung Cancer Clinical Trial using Tissue Collection

Dartmouth-Hitchcock Medical Center - Recruiting 18 years or older.
- Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer.
Tissue Collection

Non Small Cell Lung Cancer Clinical Trial

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy - Recruiting 18 years or older.
- An Exploratory Study of the Performance of Mass-Spectrometry Based Test Veristrat in Prediction of Benefit of First Line NSCLC Patients From Treatment With Standard Chemotherapy Regimens.

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]; gemcitabine; cisplatin

Hoffmann-La Roche - Recruiting 18 years or older.
- A Multiple Center, Open-label, Randomized Phase III Study to Evaluate the Efficacy and Safety of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as the First-line Treatment for Stage IIIB/IV NSCLC Patients With Mutations in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor (EGFR) in Their Tumor.
erlotinib [Tarceva]; gemcitabine; cisplatin

Small Cell Lung Cancer Clinical Trial using Chloroquine, A-CQ 100

Maastricht Radiation Oncology - Recruiting 18 years or older.
- Chloroquine as an Anti-autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients: A Phase 1 Trial.
Chloroquine, A-CQ 100

Non-small Cell Lung Cancer Clinical Trial using Induction chemotherapy and concurrent radiation; Consolidation: Radiation therapy to metastatic sites

Leo W. Jenkins Cancer Center - Recruiting 18 years or older.
- A Pilot Study Treating Patients With Minimal Stage IV Non-Small Cell Lung Cancer (NSCLC) With Curative Intent.
Induction chemotherapy and concurrent radiation; Consolidation: Radiation therapy to metastatic sites

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]

Hoffmann-La Roche - Recruiting 18 years or older.
- Phase IIIb, Open-label Study of Erlotinib (Tarcevar) Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor (ESSENCE).
erlotinib [Tarceva]

Lung Cancer Clinical Trial using Afatinib; Radiation; Cisplatin; Pemetrexed; Surgery

Massachusetts General Hospital - Recruiting 18 years or older.
- Afatinib Sequenced With Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial.
Afatinib; Radiation; Cisplatin; Pemetrexed; Surgery

Non-small Cell Lung Cancer, or Malignant Pleural Effusion Clinical Trial using Bevacizumab

Guangzhou Medical University - Recruiting 18 years or older.
- Intrapleural Bevacizumab Injection for Treating Malignant Pleural Effusion in Non-small Cell Lung Cancer.
Bevacizumab

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial using MLN8237 and Erlotinib

Fox Chase Cancer Center - Recruiting 18 years or older.
- A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, In Combination With Erlotinib In Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer.
MLN8237 and Erlotinib

Small Cell Lung Carcinoma Clinical Trial using Ipilimumab; Placebo matching Ipilimumab; Etoposide; Cisplatin; Carboplatin

Bristol-Myers Squibb - Recruiting 18 years or older.
- Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab Plus Etoposide/Platinum Versus Etoposide/Platinum in Subjects With Newly Diagnosed Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC).
Ipilimumab; Placebo matching Ipilimumab; Etoposide; Cisplatin; Carboplatin

Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, or Irin Clinical Trial using Carfilzomib; Irinotecan

Cancer Research and Biostatistics Clinical Trials Consortium - Recruiting 18 years or older.
- Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy.
Carfilzomib; Irinotecan

Lung Cancer - Non Small Cell Clinical Trial using Ipilimumab; Placebo; Paclitaxel; Carboplatin

Bristol-Myers Squibb - Recruiting 18 years or older.
- Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC).
Ipilimumab; Placebo; Paclitaxel; Carboplatin

Non-small Cell Lung Cancer Patients Clinical Trial using 18F-FDG-PET scan

University of Aarhus - Recruiting 18 years or older.
- Early Changes in 18F-fluorodeoxyglucose Positron Emissions Tomography (18F-FDG-PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI).
18F-FDG-PET scan

Non-Small Cell Lung Cancer Clinical Trial using Custirsen + Docetaxel; Docetaxel

Teva Pharmaceutical Industries - Recruiting 18 years or older.
- A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer.
Custirsen + Docetaxel; Docetaxel

Lung Cancer, or Non-Small Cell Lung Cancer Clinical Trial using MEK162; Erlotinib

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- A Phase I/IB Trial of MEK162 in Combination With Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS or EGFR Mutation.
MEK162; Erlotinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using afatinib; erlotinib

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy.
afatinib; erlotinib

Colorectal Cancer, or Non-Small Cell Lung Cancer Clinical Trial

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- Correlation of Single Nucleotide Polymorphism (SNP) Profile of Domain III of EGFR to Skin and/or Eye Toxicity and Disease Response to Treatment With Cetuximab or Panitumumab - SNP and Cetuximab or Panitumumab Response.

Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Clinical Trial using technetium Tc 99m-labeled macroaggregated albumin; 99mTc-DTPA; single photon emission computed tomography; computed tomography

University of Washington - Recruiting 19 years or older.
- Pulmonary Functional Imaging for Radiation Treatment Planning for Lung Cancer.
technetium Tc 99m-labeled macroaggregated albumin; 99mTc-DTPA; single photon emission computed tomography; computed tomography

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- AVAdeno: Non-interventional Study of Avastin 1st Line Therapy in Adenocarcinoma Patients of the Lung.

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]

Hoffmann-La Roche - Recruiting 18 years or older.
- Open Label Study of Erlotinib (Tarcevar) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations.
erlotinib [Tarceva]

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Efficacy and Safety of erLotinib (Tarcevar ) Therapy in patiEnts With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) , Subtype adEnocarcinoma, Who Have Good performaNce sTatus (PS 0-1) - ELEMENT.

Lung Cancer, or Metastatic Cancer Clinical Trial using computed tomography; 3-dimensional conformal radiation therapy; fludeoxyglucose F 18; radiation therapy treatment planning/simulation

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- Prospective Evaluation of PET-CT Scan in Patients With Non-operable or Non-resectable NSCLC Treated by Radical 3-Dimensional Conformal Radiation Therapy.
computed tomography; 3-dimensional conformal radiation therapy; fludeoxyglucose F 18; radiation therapy treatment planning/simulation

Non-Small Cell Lung Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- THE SURVIVAL OF NON SMALL CELL LUNG CARCINOMA EGFR NON-MUTATED (WILD TYPE) PATIENTS TREATED WITH ERLOTINIB (TARCEVA) AFTER THE FAILURE OF AT LEAST ONE CHEMOTHERAPY REGIMEN..

Non-small Cell Lung Cancer (NSCLC) Clinical Trial using Endocutter

Ethicon Endo-Surgery - Recruiting 18 years or older.
- A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures.
Endocutter

Non Small Cell Lung Cancer (NSCLC) Clinical Trial using SPI-1620 & Docetaxel; Docetaxel

Spectrum Pharmaceuticals, Inc - Recruiting 18 years or older.
- A 2-Part Phase 2 Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy.
SPI-1620 & Docetaxel; Docetaxel

Non-small-cell Lung Cancer Clinical Trial

Guangdong Association of Clinical Trials - Recruiting 18 years or older.
- A Prospective Epidemiologic and Clinical Feature Study of Non-Small Cell Lung Cancer (NSCLC) Patients With ALK Positive in China.

Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib

Eli Lilly and Company - Recruiting 18 years or older.
- A Randomized, Controlled Phase 2 Study Evaluating LY2875358 Plus Erlotinib Versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations Who Have Disease Control After an 8-Week Lead-In Treatment With Erlotinib.
LY2875358; Erlotinib

Squamous Non Small Cell Lung Cancer Clinical Trial using Necitumumab; Paclitaxel; Carboplatin

Eli Lilly and Company - Recruiting 18 years or older.
- A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC).
Necitumumab; Paclitaxel; Carboplatin

Carcinoma, Non-Small-Cell Lung Clinical Trial using LY2875358; Erlotinib

Eli Lilly and Company - Recruiting 18 years or older.
- A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib.
LY2875358; Erlotinib

Lung Cancer Clinical Trial using Minocycline; Placebo; Questionnaires

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer.
Minocycline; Placebo; Questionnaires

Neoplasms, Neoplasm Metastasis, Melanoma, Carcinoma, Non-Small-Ce Clinical Trial using LY3009120 capsule

Eli Lilly and Company - Recruiting 18 years or older.
- A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer.
LY3009120 capsule

Extensive Stage Small Cell Lung Cancer Clinical Trial using bioelectric impedance analysis

Comprehensive Cancer Center of Wake Forest University - Recruiting 18 years or older.
- Investigating the Prognostic Importance of Bioelectrical Impedance Phase Angle in Adults Treated for Small Cell Lung Cancer.
bioelectric impedance analysis

Squamous Non-small Cell Lung Cancer Clinical Trial using Necitumumab; Gemcitabine; Cisplatin

Eli Lilly and Company - Recruiting 20 years or older.
- An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination With Gemcitabine and Cisplatin in the First-Line Treatment of Patients With Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC).
Necitumumab; Gemcitabine; Cisplatin

Non Small Cell Lung Cancer Clinical Trial using Gefitinib; Tremelimumab

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years or older.
- Phase I, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Tremelimumab in Combination With Gefitinib in EGFR Mutant NSCLC Patients.
Gefitinib; Tremelimumab

Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC, or Metastatic Clinical Trial using Cabazitaxel-XRP6258

University of Alabama at Birmingham - Recruiting 19 years or older.
- Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients.
Cabazitaxel-XRP6258

Small Cell Lung Cancer Clinical Trial using Lithium

Barwon Health - Recruiting 18 years or older.
- A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer.
Lithium

NSCLC, Non-small Cell Lung Cancer, or Lung Cancer Clinical Trial using MEDI4736; Tremelimumab

MedImmune LLC - Recruiting 18 years or older.
- A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer.
MEDI4736; Tremelimumab

Non-small Cell Lung Cancer Metastatic Clinical Trial using Erlotinib

National Guard Health Affairs - Recruiting 18 years or older.
- Real Life Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer in the Middle Eastern Countries (REALME).
Erlotinib

Non Small Cell Lung Cancer Clinical Trial using I-131-NM404; I124-NM404

University of Wisconsin, Madison - Recruiting 18 years or older.
- NM404 as an Imaging Agent in Patients With Non-small Cell Lung Cancer (NSCLC).
I-131-NM404; I124-NM404

Non-small Cell Lung Cancer Metastatic Clinical Trial using cisplatin, docetaxel

National Guard Health Affairs - Recruiting 18 years or older.
- A Phase II Study of Docetaxel Combined With Cisplatin as the First Line Chemotherapy in Patients With Metastatic Non-small Cell Lung Cancer.
cisplatin, docetaxel

Non Small Cell Lung Cancer Clinical Trial

Maastricht Radiation Oncology - Recruiting 18 years or older.
- In Silico Clinical Trial, Comparing State of the Art Photon Modalities With Proton and 12C-ion Therapy for Stage I NSCLC: A Multicentric ROCOCO Planning Study Based on a Reference Dataset of Patients.

Small Cell Lung Cancer, or Lung Cancer Clinical Trial using Radiation Prophylactic Cranial Irradiation; Radiation Hippocampal Avoidance PCI

The Netherlands Cancer Institute - Recruiting 18 years or older.
- Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in SCLC a Randomized Phase III Trial.
Radiation Prophylactic Cranial Irradiation; Radiation Hippocampal Avoidance PCI

Colorectal Cancer Clinical Trial using Dacomitinib; PD-0325901; Irinotecan; Docetaxel; Capecitabine

The Netherlands Cancer Institute - Recruiting 18 years or older.
- Phase I/II Study With the Combination of Dacomitinib and PD-0325901 in Advanced KRAS Mutation Positive Colorectal, Non-small Cell Lung and Pancreatic Cancer.
Dacomitinib; PD-0325901; Irinotecan; Docetaxel; Capecitabine

Small Cell Lung Cancer Clinical Trial using gemcitabine; observation group

Fudan University - Recruiting 18 years or older.
- Randomized Controlled Trial of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients Receiving Etoposide Combined With Platinum Based First-line Chemotherapy.
gemcitabine; observation group

Melanoma, Ovarian Cancer, Renal Cell Cancer, or Non-small Cell Lu Clinical Trial using IDC-G305

Immune Design - Recruiting 18 years to 80 years.
- A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer.
IDC-G305

Non-small Cell Lung Cancer Clinical Trial using Dacomitinib

Pfizer - Recruiting 18 years or older.
- Phase 2 Open Label Trial Of Oral Intermittent Dacomitinib In Patients With Advanced NSCLC.
Dacomitinib

Non-small Cell Lung Cancer(NSCLC) Clinical Trial using erlotinib; docetaxel

National Taiwan University Hospital - Recruiting 18 years or older.
- An Open-label, Randomized, Phase II Study of Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of Stage IIIA Lung Adenocarcinoma With Epidermal Growth Factor Receptor Gene Mutation..
erlotinib; docetaxel

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial using PET/CT

National Cancer Institute, Naples - Recruiting 18 years or older.
- Study of the Role of Metabolic Response Measured by PET/CT Scan After 1 Cycle of Chemotherapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC).
PET/CT

Non-small Cell Lung Cancer Clinical Trial using Bevacizumab; Paclitaxel; Carboplatin

Biocad - Recruiting 18 years to 70 years.
- International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastinr (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) Patients.
Bevacizumab; Paclitaxel; Carboplatin

Tumors, Pancreatic Cancer, Non-small Cell Lung Cancer, or Esophag Clinical Trial using GS-5745 monotherapy and in combination with chemotherapy

Gilead Sciences - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors.
GS-5745 monotherapy and in combination with chemotherapy

Non-Small Cell Lung Cancer Clinical Trial using LDK378; pemetrexed; docetaxel

Novartis - Recruiting 18 years or older.
- A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib.
LDK378; pemetrexed; docetaxel

Recurrent Small Cell Lung Cancer Clinical Trial using SC16LD6.5

Stem CentRx, Inc. - Recruiting 18 years or older.
- Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients With Recurrent Small Cell Lung Cancer.
SC16LD6.5

Solid Tumors, or Non-small Cell Lung Cancer Clinical Trial using oral 5-azacitidine in combination with romidepsin

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- Phase I Trial of Oral 5-azacitidine With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer.
oral 5-azacitidine in combination with romidepsin

Non-small Cell Lung Cancer Clinical Trial using MSC2156119J; Gefitinib; Pemetrexed; Cisplatin

Merck KGaA - Recruiting 18 years or older.
- A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare MSC2156119J Combined With Gefitinib Versus Chemotherapy as Second-line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to First-line Gefitinib.
MSC2156119J; Gefitinib; Pemetrexed; Cisplatin

Non-small Cell Lung Cancer Clinical Trial using communication intervention; Real Time Registry and data feedback only

University of North Carolina, Chapel Hill - Recruiting 21 years or older.
- Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention.
communication intervention; Real Time Registry and data feedback only

Lung Cancer Clinical Trial using Carboplatin; Pemetrexed; Bevacizumab; Cetuximab; Cixutumumab

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- BATTLE-FL: A Biomarker-Integrated Study in Patients With Advanced Non-Small Cell Lung Cancer Treated in the Front-Line (FL) Setting.
Carboplatin; Pemetrexed; Bevacizumab; Cetuximab; Cixutumumab

Lung Cancer Clinical Trial using bexarotene; capecitabine; carboplatin; cisplatin; docetaxel; tretinoin

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Trial of Bexarotene (Targretin) Capsules With Tretinoin and Chemotherapy in Patients With Advanced Non-small-cell Lung Cancer.
bexarotene; capecitabine; carboplatin; cisplatin; docetaxel; tretinoin

Advanced Malignancies, Non-small Cell Lung Cancer Clinical Trial using MGCD265+erlotinib; MGCD265+docetaxel

MethylGene Inc. - Recruiting 18 years or older.
- A Phase I/II Study of MGCD265 in Combination With Erlotinib or Docetaxel in Subjects With Advanced Malignancies and in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC).
MGCD265+erlotinib; MGCD265+docetaxel

Non-Small Cell Lung Cancer Clinical Trial using erlotinib [Tarceva]; Placebo; Onartuzumab [MetMAb]

Hoffmann-La Roche - Recruiting 18 years or older.
- A RANDOMIZED, PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ONARTUZUMAB (MetMAb) IN COMBINATION WITH ERLOTINIB AS SECOND- OR THIRD-LINE TREATMENT FOR PATIENTS WITH MET-POSITIVE INCURABLE STAGE IIIB/IV NON-SMALL CELL LUNG CANCER.
erlotinib [Tarceva]; Placebo; Onartuzumab [MetMAb]

Carcinoma, Non-Small-Cell Lung Clinical Trial using BIBW 2992; Sirolimus (rapamycin)

Boehringer Ingelheim Pharmaceuticals - Recruiting 18 years or older.
- A Phase Ib Open Label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Sirolimus in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib.
BIBW 2992; Sirolimus (rapamycin)

Self Efficacy, or Drug Toxicity Clinical Trial using Erlotinib or Gefitinib

Anhui Medical University - Recruiting 18 years to 75 years.
- An Open,Multi Center Trial to Evaluate the Efficacy and Safety of High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced Non-Small Cell Lung Cancer Patients After Failure of Standard Dose EGFR-TKIs.
Erlotinib or Gefitinib

Brain Metastases From Non-small Cell Lung Cancer Clinical Trial using Veliparib; Placebo

AbbVie - Recruiting 18 years or older.
- A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer.
Veliparib; Placebo

Recurrent Small Cell Lung Cancer Clinical Trial using linsitinib; topotecan hydrochloride; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC).
linsitinib; topotecan hydrochloride; laboratory biomarker analysis; pharmacological study

Stage IV Non-small Cell Lung Cancer Clinical Trial using erlotinib; bevacizumab; laboratory biomarker analysis

Academic and Community Cancer Research United - Recruiting 18 years or older.
- A Randomized Phase II Trial of Erlotinib Alone or In Combination With Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
erlotinib; bevacizumab; laboratory biomarker analysis

Non-small Cell Lung Cancer Clinical Trial using Anlotinib hydrochloric capsule; Placebo Capsule

Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd - Recruiting 18 years to 70 years.
- .
Anlotinib hydrochloric capsule; Placebo Capsule

Non-small Cell Lung Cancer Clinical Trial using RTA 408 Capsules

Reata Pharmaceuticals, Inc. - Recruiting 18 years to 75 years.
- An Open-Label, Single-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer.
RTA 408 Capsules

Non-small Cell Lung Cancer, or Metastasis From Other Cancers Clinical Trial using Stereotactic Radiation

University Health Network, Toronto - Recruiting 18 years or older.
- Lung Stereotactic Radiation Therapy for Patients With Non-small Cell Lung Cancer and Other Cancers.
Stereotactic Radiation

Non Small Cell Lung Cancer Clinical Trial using Stereotactic Body Radiation Therapy

University Health Network, Toronto - Recruiting 18 years or older.
- MRI Assessment of Post-Radiation Change Following Stereotactic Body RT for Non-Small Cell Lung Cancer: A Pilot Study.
Stereotactic Body Radiation Therapy

Lung Cancer Clinical Trial using LDE225, Etoposide and Cisplatin

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of the Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC).
LDE225, Etoposide and Cisplatin

Lung Cancer, or Non-small Cell Lung Cancer (NSCLC) Clinical Trial using Dasatinib - 1A; Afatinib - 1A; Dasatinib - 1B; Afatinib - 1B

H. Lee Moffitt Cancer Center and Research Institute - Recruiting 18 years or older.
- Phase I Trial Evaluating Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Afatinib (BIBW 2992) in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Non-small Cell Lung Cancer (NSCLC).
Dasatinib - 1A; Afatinib - 1A; Dasatinib - 1B; Afatinib - 1B

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial using Gemcitabine; Pemetrexed; Cisplatin

National Cancer Institute, Naples - Recruiting 70 years or older.
- A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC..
Gemcitabine; Pemetrexed; Cisplatin

Non-Small Cell Lung Cancer Clinical Trial using Icotinib

Zhejiang Beta Pharma Inc. - Recruiting 70 years to 80 years.
- An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation.
Icotinib

Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell L Clinical Trial using therapeutic lymphadenectomy; stereotactic body radiation therapy; quality-of-life assessment

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Pilot Study of Stereotactic Body Radiation Therapy (SBRT) After TEMLA for Stage III and IV (Oligometastatic) Non-Small Cell Lung Cancer.
therapeutic lymphadenectomy; stereotactic body radiation therapy; quality-of-life assessment

Non Small Cell Lung Cancer Clinical Trial using Bevacizumab; recombinant human endostatin

Zhejiang University - Recruiting 18 years to 75 years.
- Phase II Study of Intrapleural Administration of Bevacizumab Versus Recombinant Human Endostatin (Endostar) for Refractory Malignant Pleural Effusions in Advanced Non-small Cell Lung Cancer (NSCLC).
Bevacizumab; recombinant human endostatin

Non Small Cell Lung Cancer Clinical Trial using EGFR tyrosine kinase inhibitor; EGFR tyrosine kinase inhibitor with chemotherapy

Zhejiang University - Recruiting 18 years to 75 years.
- Phase II Study of Continuation of Tyrosine Kinase Inhibitor (TKI) With or Without Chemotherapy Beyond Gradual Progression in Advanced Non-small Cell Lung Cancer (NSCLC).
EGFR tyrosine kinase inhibitor; EGFR tyrosine kinase inhibitor with chemotherapy

Lung Cancer, Non-Small Cell Clinical Trial using Collection of tumor and blood samples

GlaxoSmithKline - Recruiting 18 years or older.
- Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma.
Collection of tumor and blood samples

Non Small Cell Lung Cancer Clinical Trial

National University Hospital, Singapore - Recruiting N/A or older.
- A Retrospective Study of Biomarkers in Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer Clinical Trial using Monosialoganglioside(GM1); normal saline

Sun Yat-sen University - Recruiting N/A or older.
- A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by First-line Chemotherapy Contained Cisplatin in Non-small Cell Lung Cancer Patients..
Monosialoganglioside(GM1); normal saline

Non Small Cell Lung Cancer Clinical Trial using Everolimus; Pemetrexed; Carboplatin; Bevacizumab

Cancer Research and Biostatistics Clinical Trials Consortium - Recruiting 18 years or older.
- Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer.
Everolimus; Pemetrexed; Carboplatin; Bevacizumab

Non Small Cell Lung Cancer Clinical Trial using Afatinib

Massachusetts General Hospital - Recruiting 18 years or older.
- Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation.
Afatinib

Non Small Cell Lung Cancer, or Lung Cancer Clinical Trial using defactinib (VS-6063)

Verastem, Inc. - Recruiting 18 years or older.
- Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer.
defactinib (VS-6063)

Non Small Cell Lung Cancer, or Chronic Obstructive Pulmonary Dise Clinical Trial

University of Virginia - Recruiting 18 years or older.
- The Use of Circulating Tumor Cells in Non-Small Cell Lung Cancer: Novel Isolation Methods and Clinical Applications.

EGFR Positive Non-small Cell Lung Cancer Clinical Trial using Dacomitinib (PF-00299804); Gefitinib

SFJ Pharmaceuticals, Inc. - Recruiting 18 years or older.
- ARCHER 1050: A Randomized, Open Label Phase 3 Efficacy and Safety Study Of Dacomitinib (PF-00299804) Vs. Gefitinib For The First-Line Treatment Of Locally Advanced or Metastatic NSCLC In Subjects With EGFR Activating Mutations.
Dacomitinib (PF-00299804); Gefitinib

Non-small-cell Lung Cancer Clinical Trial using Pemetrexed; Bevacizumab

Hellenic Oncology Research Group - Recruiting 18 years or older.
- Pemetrexed Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC).
Pemetrexed; Bevacizumab

Non-small-cell Lung Cancer Clinical Trial using Docetaxel; Bevacizumab

Hellenic Oncology Research Group - Recruiting 18 years or older.
- Docetaxel Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC.
Docetaxel; Bevacizumab

Lung Cancer Clinical Trial using EBUS-TBNA

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Diagnostic Utility of Endobronchial Ultrasound Guided Mediastinal Lymph Node Sampling in Clinical Stage I and II Non Small Cell Lung Cancer.
EBUS-TBNA

Endometrial Adenocarcinomas, Neuroendocrine Tumors, or Small-cell Clinical Trial using lurbinectedin (PM01183); Doxorubicin

PharmaMar - Recruiting 18 years to 75 years.
- Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors.
lurbinectedin (PM01183); Doxorubicin

Non-Small Cell Lung Cancer Clinical Trial using Peripherally located lung tumor; Centrally located lung tumor

University of Florida - Recruiting 18 years or older.
- Hypofractionated, Image-Guided Radiation Therapy With Proton Therapy for Stage I Non-Small Cell Lung Cancer.
Peripherally located lung tumor; Centrally located lung tumor

Non-small Cell Lung Cancer, or Unresectable Clinical Trial

University of Athens - Recruiting 18 years or older.
- Open-label Study of Bevacizumab (AVASTINr) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer.

Patients Must Have Histologically or Cytologically Confirmed Non- Clinical Trial using Paclitaxel, Carboplatin, Bevacizumab, and Metformin; Paclictaxl, Carboplatin, and Bevcizumab.

Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older.
- A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Previously Untreated Advanced/Metastatic Pulmonary Adenocarcinoma.
Paclitaxel, Carboplatin, Bevacizumab, and Metformin; Paclictaxl, Carboplatin, and Bevcizumab.

Lung Cancer, Non Small Cell Lung Cancer, or Solid Tumors Clinical Trial using Stereotactic Body Radiation

New Mexico Cancer Care Alliance - Recruiting 18 years or older.
- INST 0810: Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung.
Stereotactic Body Radiation

Stage IV Small Cell Lung Cancer Clinical Trial using OMP-59R5; Etoposide; Placebo; Cisplatin

OncoMed Pharmaceuticals, Inc. - Recruiting 18 years to 90 years.
- A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Cisplatin in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE).
OMP-59R5; Etoposide; Placebo; Cisplatin

Non-small Cell Lung Cancer Clinical Trial using HLA-A*0201restricted URLC10 peptides with adjuvant

Shiga University - Recruiting 20 years to 85 years.
- Phase I/II Study Using Epitope Peptide Restricted to HLA-A*24 (URLC10) in Patients With Disease Controlled Advanced Non-small Cell Lung Cancer.
HLA-A*0201restricted URLC10 peptides with adjuvant

Small Cell Lung Cancer Clinical Trial using desipramine

Stanford University - Recruiting 18 years or older.
- A Phase IIa Intrapatient Dose Escalation Study of Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors.
desipramine

Carcinoma, Non-Small Cell Lung, or Carcinoma, Small Cell Lung Clinical Trial using 13-C-glucose

James Graham Brown Cancer Center - Recruiting 18 years to 75 years.
- Preoperative Metabolomic Analysis of Primary Lung Cancer: A Translational Clinical Trial of the Brown Cancer Center.
13-C-glucose

Non-small Cell Lung Cancer Clinical Trial using HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides

Shiga University - Recruiting 20 years to 85 years.
- Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*02 (URLC10) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy.
HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides

Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell L Clinical Trial using entinostat; azacitidine; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Study of Entinostat in Combination With 5-Azacytidine in Patients With Recurrent Advanced Non-Small Cell Lung Cancer.
entinostat; azacitidine; pharmacological study; laboratory biomarker analysis

Non-small Cell Lung Cancer Clinical Trial using Blood samples

Maastricht Radiation Oncology - Recruiting N/A or older.
- Use of Blood Biomarkers to Predict Overall Survival for Non-Small-cell Lung Cancer (NSCLC) Patients Treated With (Chemo)Radiotherapy..
Blood samples

Metastatic Non-Small Cell Lung Cancer, Metastatic Colon Cancer, o Clinical Trial using CTLA-4 Antibody; Hypofractionated Radiotherapy

Western Regional Medical Center - Recruiting 18 years or older.
- A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST).
CTLA-4 Antibody; Hypofractionated Radiotherapy

Non-small Cell Lung Cancer Clinical Trial using Nimotuzumab and TP regimen; TP regimen

Tianjin Medical University Cancer Institute and Hospital - Recruiting 18 years to 70 years.
- The Study of Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for Patient With the Advanced Non-small Cell Lung Cancer( NSCLC).
Nimotuzumab and TP regimen; TP regimen

Non-small Cell Lung Cancer Clinical Trial using gefitinib

Guangdong Association of Clinical Trials - Recruiting 18 years to 75 years.
- Intercalating and Maintenance Use of Iressa vs. Chemotherapy in Selected Advanced NSCLC: a Randomised Study.
gefitinib

Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Non-small-ce Clinical Trial using MORAb-066

Morphotek - Recruiting 18 years or older.
- A Phase I Study of the Safety, Tolerability, and PK of MORAb-066, a Humanized Monoclonal Antibody to Human TF, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or NSCLC (Adenocarcinoma) Malignancies.
MORAb-066

Recurrent Non-small Cell Lung Cancer, or Stage IV Non-small Cell Clinical Trial using paclitaxel albumin-stabilized nanoparticle formulation; laboratory biomarker analysis

Fred Hutchinson Cancer Research Center - Recruiting 18 years or older.
- A Phase II Study of Weekly ABRAXANEr (Nab-paclitaxel) for Patients With Advanced NSCLC With EGFR Mutations Following Front-line Therapy With EGFR Tyrosine Kinase Inhibitors.
paclitaxel albumin-stabilized nanoparticle formulation; laboratory biomarker analysis

Stage I-III Small Cell Lung Cancer Clinical Trial using Radiotherapy

Maastricht Radiation Oncology - Recruiting 18 years or older.
- Concurrent Chemo-radiotherapy With IMRT for Stage I-III Small Cell Lung Cancer.
Radiotherapy

Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Nec Clinical Trial using 18F-fluoromisonidazole; fluorescence angiography; laboratory biomarker analysis; infrared thermography; magnetic resonance imaging; therapeutic conventional surgery; [18F]-ML-10; fludeoxyglucose F 18; rubidium Rb-82

National Cancer Institute (NCI) - Recruiting N/A or older.
- Tumor Angiogenesis in Non-Small Cell Lung (NSCLC), Colorectal, Breast, Esophageal, Head and Neck Cancer: Radiology-Pathology and Prognostic Correlation.
18F-fluoromisonidazole; fluorescence angiography; laboratory biomarker analysis; infrared thermography; magnetic resonance imaging; therapeutic conventional surgery; [18F]-ML-10; fludeoxyglucose F 18; rubidium Rb-82

Lung Cancer Clinical Trial using carboplatin; cisplatin; gemcitabine hydrochloride

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A British Thoracic Oncology Group Phase III Trial of Gemcitabine Plus Cisplatin at 80mg/m Versus Gemcitabine Plus Carboplatin At 50 mg/m Versus Gemcitabine Plus Carboplatin AUC 6 in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC).
carboplatin; cisplatin; gemcitabine hydrochloride

Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Clinical Trial using hypofractionated radiation therapy; laboratory biomarker analysis; image-guided radiation therapy; carboplatin; paclitaxel; stereotactic body radiation therapy

Jonsson Comprehensive Cancer Center - Recruiting 18 years or older.
- Image-Guided Hypofractionated Radiotherapy With Stereotactic Boost and Chemotherapy for Inoperable Stage II-III Non-Small Cell Lung Cancer.
hypofractionated radiation therapy; laboratory biomarker analysis; image-guided radiation therapy; carboplatin; paclitaxel; stereotactic body radiation therapy

Non-small-cell Lung Cancer Clinical Trial using Icotinib+WBRT

Zhejiang Beta Pharma Inc. - Recruiting 18 years to 75 years.
- A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases.
Icotinib+WBRT

Lung Cancer Clinical Trial using docetaxel; erlotinib hydrochloride; pemetrexed disodium; fluorescence in situ hybridization; mutation analysis; proteomic profiling; immunohistochemistry staining method; laboratory biomarker analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry; breath test

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Randomized Proteomic Stratified Phase III Study of Second-Line Erlotinib Versus Chemotherapy in Patients With Inoperable Non Small Cell Lung Cancer.
docetaxel; erlotinib hydrochloride; pemetrexed disodium; fluorescence in situ hybridization; mutation analysis; proteomic profiling; immunohistochemistry staining method; laboratory biomarker analysis; matrix-assisted laser desorption/ionization time of flight mass spectrometry; breath test

Lung Cancer Clinical Trial using carboplatin; nitroglycerin; paclitaxel

National Cancer Institute (NCI) - Recruiting 40 years to 80 years.
- A Phase II, Multinational and Multicenter, Randomized, Controlled Study of Paclitaxel and Carboplatin With vs Without Nitroglycerin in Patients With Untreated Advanced Non-small Cell Lung Cancer.
carboplatin; nitroglycerin; paclitaxel

Lung Cancer Clinical Trial using cisplatin; gemcitabine hydrochloride; adjuvant therapy; conventional surgery; neoadjuvant therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Study of Preoperative Versus Postoperative Gemcitabine and Cisplatin for Patients With Stage IB-II Non-Small Cell Lung Cancer.
cisplatin; gemcitabine hydrochloride; adjuvant therapy; conventional surgery; neoadjuvant therapy

Non-Small Cell Lung Cancer Clinical Trial

University of Michigan Cancer Center - Recruiting 18 years to 80 years.
- A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung Cancer.

Non-small Cell Lung Cancer, Radiation Therapy, Locally Advanced D Clinical Trial using mid-position radiation strategy; ITV

Centre Leon Berard - Recruiting 18 years or older.
- Randomized Phase 2 Study Evaluating the Interest of Mid-position Strategy Versus ITV (Internal Target Volume) Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-resected Non-small Cell Lung Carcinoma (NSCLC)..
mid-position radiation strategy; ITV

Stage III Non-small Cell Lung Cancer Clinical Trial using Chemotherapy; ERBITUX; Radiotherapy

Intergroupe Francophone de Cancerologie Thoracique - Recruiting 18 years to 70 years.
- Phase II Study of Pemetrexed + Cetuximab + Cisplatin With Concurrent Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC).
Chemotherapy; ERBITUX; Radiotherapy

Non Squamous Non Small Cell Lung Cancer Clinical Trial using Docetaxel; Paclitaxel; Bevacizumab

Intergroupe Francophone de Cancerologie Thoracique - Recruiting 18 years or older.
- Phase III Study Comparing the Efficacy of Paclitaxel-bevacizumab With Docetaxel in 2nd or 3rd Line of Treatment of Non Squamous Non Small Cells Lung Cancer.
Docetaxel; Paclitaxel; Bevacizumab

Carcinoma, Small Cell Clinical Trial using Temozolomide

Chinese PLA General Hospital - Recruiting 18 years to 75 years.
- Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer.
Temozolomide

Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Clinical Trial using breath test; laboratory biomarker analysis

Fox Chase Cancer Center - Recruiting 18 years or older.
- A Single-center Study to Evaluate the Feasibility of a Novel NA-NOSE for Monitoring Response to and Detecting Recurrence After Surgery or Radiation in Early Stage Lung Cancer.
breath test; laboratory biomarker analysis

Lung Cancer, or Non Small Cell Lung Cancer Clinical Trial using Experimental: Preoperative and early postoperative rehabilitation; Experimental: Preoperative and late postoperative rehabilitation; Experimental: Early postoperative rehabilitation alone; Other: Usual care

Rigshospitalet, Denmark - Recruiting 18 years or older.
- Perioperative Rehabilitation in Operation for Lung Cancer.
Experimental: Preoperative and early postoperative rehabilitation; Experimental: Preoperative and late postoperative rehabilitation; Experimental: Early postoperative rehabilitation alone; Other: Usual care

NSCLC Clinical Trial using Olaparib; Cisplatin; Radiation

The Netherlands Cancer Institute - Recruiting 18 years or older.
- Olaparib Dose Escalating Trial in Patients Treated With Radiotherapy With or Without Daily Dose Cisplatin for Locally Advanced Non-small Cell Lung Carcinoma.
Olaparib; Cisplatin; Radiation

NSCLC, EGFR Gene Amplification, Advanced Cancer, Stage IIIB NSCLC Clinical Trial using Gefitinib and Metformin; Gefitinib and placebo

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University - Recruiting 18 years to 75 years.
- A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gefitinib and Metformin in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer.
Gefitinib and Metformin; Gefitinib and placebo

Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer, or S Clinical Trial using Cisplatin; Pemetrexed; Gemcitabine

Western Regional Medical Center - Recruiting 18 years or older.
- Neoadjuvant Chemotherapy for Non-metastatic Non-small Cell Lung Cancer.
Cisplatin; Pemetrexed; Gemcitabine

Carcinoma, Non-Small-Cell Lung Clinical Trial using BIBW 2992

University College, London - Recruiting 18 years or older.
- Phase II Trial of BIBW 2992 in Suspected Mutant EGFR Lung Cancer Patients Unfit for Chemotherapy.
BIBW 2992

Non-small Cell Lung Cancer (NSCLC) Clinical Trial using VATS for confirmed non-small cell lung cancer (NSCLC)

Ethicon Endo-Surgery (Europe) GmbH - Recruiting 18 years or older.
- Real World Outcomes of Video-Assisted Thoracoscopic Surgery for Lung Cancer Using ECHELON FLEXT Powered ENDOPATHr Stapler: a Prospective European Multicenter Study.
VATS for confirmed non-small cell lung cancer (NSCLC)

Lung Cancer Clinical Trial using Pazopanib

UNC Lineberger Comprehensive Cancer Center - Recruiting 18 years or older.
- A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab.
Pazopanib

Carcinoma, Non-Small-Cell Lung Clinical Trial using Astagalus-based Formula: Qingshu-Yiqi-Tang

Chang Gung Memorial Hospital - Recruiting 18 years to 75 years.
- Efficacy Study of Chinese Medicine on Modulating Immune Alterations in Advanced Stage, Non-small Cell Lung Cancer Patients Receiving 1st Line Doublet Chemotherapy and 2nd Line Target Therapy.
Astagalus-based Formula: Qingshu-Yiqi-Tang

Lung Cancer Clinical Trial using therapeutic thoracoscopy; videothoracoscopy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (ó 2 CM) Peripheral Non-Small Cell Lung Cancer.
therapeutic thoracoscopy; videothoracoscopy

Lung Cancer Clinical Trial using EBUS-TBNA

University Health Network, Toronto - Recruiting 18 years or older.
- Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT).
EBUS-TBNA

Non-small Cell Lung Cancer Metastatic, or Non-small Cell Lung Can Clinical Trial

Chonnam National University Hospital - Recruiting 19 years to 80 years.
- Phase 4 Study of Response to EGFR-TKI and Correlation With C-met Expression and EGFR Gene Mutation in NSCLC Patients Treated With Erlotinib.

Carcinoma, Non Small Cell Lung Clinical Trial using Taxotere; Pemetrexed

Chonnam National University Hospital - Recruiting 18 years or older.
- A Randomized Phase III Study of TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer.
Taxotere; Pemetrexed

Non-small Cell Lung Cancer Clinical Trial using Gefitinib

Asan Medical Center - Recruiting 19 years or older.
- First Line Gefitinib Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) by the FDG-PET Metabolic Response.
Gefitinib

Non Small Cell Lung Cancer Clinical Trial using decitabine in combination with genistein

Uman Pharma - Recruiting 18 years to 75 years.
- A Phase I/IIa Dose-Escalation Study of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) Subjects.
decitabine in combination with genistein

Carcinoma, Non Small Cell Lung Clinical Trial using CT Perfusion

University of Pittsburgh - Recruiting 18 years or older.
- CTP (Computed Tomography Perfusion) Imaging of Lung Cancer.
CT Perfusion

Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Gen Clinical Trial

University Health Network, Toronto - Recruiting 18 years or older.
- Integrated Molecular Profiling in Advanced Cancers Trial.

Small Cell Lung Cancer Clinical Trial using Adaptive Radiation

AHS Cancer Control Alberta - Recruiting 18 years or older.
- Pilot Project of Adaptive Thoracic Radiotherapy for Small Cell Lung Cancer.
Adaptive Radiation

Brain Metastasis, or Non Small Cell Lung Cancer Clinical Trial using whole brain radiation(WBI); Icotinib

Guangdong Association of Clinical Trials - Recruiting 18 years to 75 years.
- Phase III Study of Icotinib Treat the Patient With Brain Metastasis EGFR-mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy.
whole brain radiation(WBI); Icotinib

Non-small Cell Lung Cancer Metastatic, or Small Cell Lung Carcino Clinical Trial using therapeutic interventions

Vanderbilt-Ingram Cancer Center - Recruiting 18 years or older.
- Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network.
therapeutic interventions

Malignant Pleural Effusion Clinical Trial using Bevacizumab; Cisplatin

Chinese PLA General Hospital - Recruiting 18 years to 60 years.
- Open-labled, Randomized, Multicenter Phase III Study of Adjuvant Chemotherapy Comparing Bevacizumab Plus Cisplatin With Cisplatin Regimen in Malignant Pleural Effusion of Advanced Stage Non-Small-Cell Lung Cancer Patients.
Bevacizumab; Cisplatin

Small Cell Carcinoma of Lung Clinical Trial using Irinotecan

Zhejiang Cancer Hospital - Recruiting 18 years to 75 years.
- Phase ? Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer.
Irinotecan

Non-small Cell Lung Cancer Stage IIIB, or Toxicity Due to Chemoth Clinical Trial using chemotherapy & WBH

Xijing Hospital - Recruiting 18 years to 75 years.
- A Randomized Contrasted Polycentric Clinical Study About Chemotherapy Combined With Whole-body Hyperthermia(WBH)to Treat Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC).
chemotherapy & WBH

Hepatocellular Cancer, Non-small Cell Lung Cancer, Renal Cell Can Clinical Trial using Avastin; Suntent; Nexavar

Medical University Innsbruck - Recruiting 18 years or older.
- Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients.
Avastin; Suntent; Nexavar

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous, or Carcinoma Clinical Trial using Docetaxel; Oxaliplatin

Korean South West Oncology Group - Recruiting 18 years or older.
- A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment.
Docetaxel; Oxaliplatin

Thoracic Neoplasms, or Non-small Cell Lung Cancer Clinical Trial using 3D conform radiotherapy

Chinese Academy of Medical Sciences - Recruiting 18 years to 70 years.
- Phase III Comparison of Postoperative 3D Conform Radiotherapy After Chemotherapy and Chemotherapy Alone in Patients With Completely Resected Stage IIIA(N2) Non-small Cell Lung Cancer.
3D conform radiotherapy

Non-small Cell Lung Cancer Clinical Trial using Gefitinib

ZhuGuangYing - Recruiting 18 years to 75 years.
- A Phase II Trial of Radiation Therapy Combined With Iressa in Patients With Locally Advanced Non-small Cell Lung Cancer With Harboring Active EGFR Mutations.
Gefitinib

Non Small Cell Lung Cancer Clinical Trial using carboplatin paclitaxel bevacizumab; Standard treatment plus nitroglycerin

Dutch Society of Physicians for Pulmonology and Tuberculosis - Recruiting 18 years or older.
- A Randomized Phase II Study of Paclitaxel-carboplatin-bevacizumab With or Without Nitroglycerin Patches in Patients With Stage IV Non-squamous-non-small Cell Lung Cancer: NVALT12.
carboplatin paclitaxel bevacizumab; Standard treatment plus nitroglycerin

Nonsmall Cell Lung Cancer Clinical Trial using Radiosurgery; Observation

Samsung Medical Center - Recruiting 18 years or older.
- Randomized Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Observation for Patients With Asymptomatic Cerebral Oligo-metastases in Non-small Cell Lung Cancer (NSCLC).
Radiosurgery; Observation

Non-Small-Cell Lung Carcinoma Clinical Trial using cisplatin, vinorlebine, cetuximab; cisplatine, etoposide, cetuximab

Institut de Canc‚rologie de la Loire - Recruiting 18 years to 70 years.
- Feasibility of Cetuximab (ERBITUXr) Associated With Concomitant Radio-chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer: a Phase II, Randomised Study.
cisplatin, vinorlebine, cetuximab; cisplatine, etoposide, cetuximab

NSCLC, or Non Small Cell Lung Cancer Clinical Trial using Cesium-131 Brachytherapy Seed

IsoRay Medical, Inc. - Recruiting N/A or older.
- Outcome Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage NSCLC.
Cesium-131 Brachytherapy Seed

Carcinoma, Non-Small-Cell Lung Clinical Trial using Endostatins; Docetaxel

Fudan University - Recruiting 18 years to 80 years.
- A Phase 2 Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients.
Endostatins; Docetaxel

Carcinoma, Non-Small-Cell Lung Clinical Trial using erlotinib plus docetaxel or pemetrexed; erlotinib

Dutch Society of Physicians for Pulmonology and Tuberculosis - Recruiting 18 years or older.
- A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study).
erlotinib plus docetaxel or pemetrexed; erlotinib

Lung Neoplasms Clinical Trial using gemcitabine, carboplatin; surgery

Hospital Authority, Hong Kong - Recruiting 18 years to 75 years.
- Phase II Study of the Response Rate of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small Cell Lung Cancer Before Surgery.
gemcitabine, carboplatin; surgery

Non-small Cell Lung Cancer Clinical Trial using Prophylactic cranial irradiation; Erlotinib /Gefitinib

Zhejiang Cancer Hospital - Recruiting 18 years to 75 years.
- A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Effective on Erlotinib or Gefitinib(RT1001).
Prophylactic cranial irradiation; Erlotinib /Gefitinib

Lung Cancer Clinical Trial using erlotinib hydrochloride; stereotactic body radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase II Trial of Erlotinib (Tarcevar) in Combination With Stereotactic Body Radiation Therapy (SBRT) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
erlotinib hydrochloride; stereotactic body radiation therapy

Non-small Cell Lung Cancer Clinical Trial using Docetaxel and Cisplatin

Gyeongsang National University Hospital - Recruiting 18 years to 75 years.
- Phase II Study of Biweekly Schedule of Docetaxel and Cisplatin in Patients With Unresectable Non-small Cell Lung Cancer.
Docetaxel and Cisplatin

Non-small Cell Lung Cancer Clinical Trial using Tarceva; Radiotherapy

Odense University Hospital - Recruiting 18 years to 90 years.
- Concomitant Tarcevar and Irradiation in Patients in Local-regionally Advanced Non-small Cell Lung Cancer. A Phase II Study.
Tarceva; Radiotherapy

Non Small Cell Lung Cancer Clinical Trial using EBUS_TBNA

University of Heidelberg - Recruiting 18 years to 80 years.
- EBUS-guided TBNA for Molecular Diagnostic of Mediastinal Lymph Nodes.
EBUS_TBNA

Lung Cancer Clinical Trial using erlotinib hydrochloride; sorafenib tosylate; DNA analysis; mutation analysis; polymerase chain reaction; protein analysis; protein expression analysis; immunohistochemistry staining method; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Multicenter, Open-label, Phase II Study of Sorafenib in Combination With Erlotinib in Non-small Cell Lung Cancer (NSCLC) Refractory to One or Two Prior Chemotherapy Regimens.
erlotinib hydrochloride; sorafenib tosylate; DNA analysis; mutation analysis; polymerase chain reaction; protein analysis; protein expression analysis; immunohistochemistry staining method; laboratory biomarker analysis

Lung Cancer Clinical Trial using cisplatin; docetaxel; quality-of-life assessment; radiation therapy; stereotactic radiosurgery

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Study of Doses Escalation on Efficacy on Cyberknife After Docetaxel-Cisplatin Concomitant Radiotherapy for Non Small Cells Lung Cancer Stage III.
cisplatin; docetaxel; quality-of-life assessment; radiation therapy; stereotactic radiosurgery

Advanced Non-Small Cell Lung Cancer Clinical Trial using Pemetrexed; Pemetrexed plus carboplatin

Gruppo Oncologico Italiano di Ricerca Clinica - Recruiting 18 years or older.
- Randomized Phase II Study of Pemetrexed Versus Pemetrexed and Carboplatin as Second Line Chemotherapy in Advanced Non-small-cell Lung Cancer (NSCLC)..
Pemetrexed; Pemetrexed plus carboplatin

Non-small Cell Lung Cancer Clinical Trial using Pemetrexed; pemetrexed and erlotinib

Montefiore Medical Center - Recruiting 18 years or older.
- A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed and Erlotinib Versus Single Agent Pemetrexed in Patients With Progressive or Recurrent Non-Small Cell Lung Cancer (NSCLC).
Pemetrexed; pemetrexed and erlotinib

Carcinoma, Non-Small-Cell Lung Clinical Trial using Gemcitabine and Docetaxel

Hospital Arnau de Vilanova - Recruiting 18 years or older.
- Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer Patients With ECOG PS 2.
Gemcitabine and Docetaxel

Locally Advanced Non Small-Cell Lung Canger Clinical Trial using Transdermal nitroglycerin

National Institute of Cancerolog¡a - Recruiting 18 years or older.
- Phase II Study That Evaluates Concurrent Chemotherapy and Radiotherapy With Nitroglycerin in Patients With Locally Advanced Non-Small Cell Lung Cancer.
Transdermal nitroglycerin

Non Small Cell Lung Cancer Clinical Trial using erlotinib

Rigshospitalet, Denmark - Recruiting 18 years or older.
- A Phase II Study of Erlotinib and Predictive Markers as First-Line Treatment of Advanced Non-Small Cell Lung Cancer for Patients Unfit for Chemotherapy.
erlotinib

Lung Cancer Clinical Trial using cisplatin; etoposide; irinotecan hydrochloride; radiation therapy

National Cancer Institute (NCI) - Recruiting 18 years to 75 years.
- Phase II Trial Irinotecan and Cisplatin Induction Chemotherapy Followed by Radiotherapy Concurrently With Etoposide/Cisplatin in Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer.
cisplatin; etoposide; irinotecan hydrochloride; radiation therapy

Small Cell Lung Cancer Clinical Trial using Irinotecan hydrochloride; Cisplatin; Krestin

University of Toyama - Recruiting 20 years to 74 years.
- Feasibility Study for Multicenter Randomized Controlled Phase III Clinical Trial of Cisplatin + Irinotecan Therapy and Cisplatin + Irinotecan + Krestin Therapy for Extensive-Stage Disease (ED) Small Cell Lung Cancer.
Irinotecan hydrochloride; Cisplatin; Krestin

Small Cell Lung Cancer Clinical Trial using Carboplatin, docetaxel

Jeroen Bosch Ziekenhuis - Recruiting 18 years to 80 years.
- A Phase II Study of Docetaxel - Carboplatin as Second Line Treatment in Patients With Refractory or Relapsed Small Cell Lung Cancer.
Carboplatin, docetaxel

Lung Cancer Clinical Trial using gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6; UFT 250mg/m2, daily for 1 year

West Japan Thoracic Oncology Group - Recruiting 20 years to 75 years.
- .
gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6; UFT 250mg/m2, daily for 1 year

Carcinoma, Non-Small-Cell Lung Clinical Trial using Chemotherapy; Radiation Therapy

Clinical Oncology Research Associates - Recruiting N/A or older.
- Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study.
Chemotherapy; Radiation Therapy